The incredibly rapid adaptation of nucleic acid tests for West Nile virus (WNV), along with declining WNV incidence in many parts of the United States, has allowed blood banks and patients to breathe much easier. However, in this issue, Custer and colleagues provide a careful and circumspect cost-effectiveness analysis of WNV screening in blood banks. Their model shows that from a population perspective, WNV testing is very costly relative to its benefits, which affect relatively few people.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.